S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.47%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.47%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.47%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
S&P 500   4,274.04 (-0.72%)
DOW   33,980.32 (-0.50%)
QQQ   328.49 (-1.14%)
AAPL   174.55 (+0.88%)
MSFT   291.32 (-0.47%)
META   174.85 (-2.57%)
GOOGL   119.55 (-1.77%)
AMZN   142.10 (-1.85%)
TSLA   911.99 (-0.84%)
NVDA   183.35 (-2.88%)
NIO   20.08 (-3.97%)
BABA   89.77 (-3.11%)
AMD   98.27 (-1.93%)
MU   61.62 (-3.51%)
T   18.42 (-0.81%)
CGC   4.06 (+7.41%)
F   16.03 (-2.43%)
GE   79.92 (-1.42%)
DIS   122.81 (-1.72%)
AMC   21.36 (-13.91%)
PYPL   99.42 (-2.61%)
PFE   49.27 (-1.18%)
NFLX   241.15 (-1.85%)
Top-Rated Stocks  
NYSE:DHR

Danaher - DHR Stock Forecast, Price & News

$297.27
-3.21 (-1.07%)
(As of 08/17/2022 05:18 PM ET)
Add
Compare
Today's Range
$295.86
▼
$300.72
50-Day Range
$238.60
▼
$302.35
52-Week Range
$233.71
▼
$333.96
Volume
2.15 million shs
Average Volume
2.71 million shs
Market Capitalization
$216.25 billion
P/E Ratio
35.01
Dividend Yield
0.33%
Price Target
$328.58

Danaher MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
9.8% Upside
$326.50 Price Target
Short Interest
Healthy
0.59% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.05mentions of Danaher in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$11.82 M Sold Last Quarter
Proj. Earnings Growth
2.40%
From $10.40 to $10.65 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Multi-Sector Conglomerates Sector

4th out of 15 stocks

Process Control Instruments Industry

6th out of 14 stocks

See Top Rated MarketRank™ Stocks Here
DHR stock logo

About Danaher (NYSE:DHR) Stock

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DHR. Sanford C. Bernstein assumed coverage on shares of Danaher in a report on Tuesday. They issued an "outperform" rating on the stock. Evercore ISI dropped their target price on shares of Danaher from $320.00 to $280.00 and set an "outperform" rating on the stock in a report on Tuesday, July 5th. William Blair reissued an "outperform" rating on shares of Danaher in a report on Friday, April 22nd. Cowen dropped their target price on shares of Danaher to $340.00 in a report on Friday, July 22nd. Finally, StockNews.com raised shares of Danaher from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 30th. One investment analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $328.58.

Danaher Stock Down 0.6 %

Danaher stock opened at $300.48 on Wednesday. The company has a 50-day simple moving average of $265.83 and a 200-day simple moving average of $269.07. The firm has a market capitalization of $218.58 billion, a P/E ratio of 35.39, a P/E/G ratio of 2.42 and a beta of 0.86. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.32 and a current ratio of 1.75. Danaher has a one year low of $233.71 and a one year high of $333.96.

Danaher (NYSE:DHR - Get Rating) last announced its earnings results on Thursday, July 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.35 by $0.41. The firm had revenue of $7.75 billion during the quarter, compared to analyst estimates of $7.29 billion. Danaher had a net margin of 20.61% and a return on equity of 18.57%. Danaher's revenue was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 EPS. As a group, equities analysts expect that Danaher will post 10.4 earnings per share for the current year.

Insider Activity at Danaher

In related news, EVP Joakim Weidemanis sold 12,000 shares of the stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $271.13, for a total value of $3,253,560.00. Following the completion of the transaction, the executive vice president now owns 74,398 shares in the company, valued at approximately $20,171,529.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Joakim Weidemanis sold 12,000 shares of the firm's stock in a transaction dated Monday, July 25th. The shares were sold at an average price of $271.13, for a total transaction of $3,253,560.00. Following the completion of the transaction, the executive vice president now owns 74,398 shares in the company, valued at approximately $20,171,529.74. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Walter G. Lohr sold 3,906 shares of the firm's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $273.84, for a total transaction of $1,069,619.04. Following the transaction, the director now owns 12,115 shares of the company's stock, valued at approximately $3,317,571.60. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Stock News Headlines

August 16, 2022 | businesswire.com
Global Lateral Flow Assay Market Report to 2029 - Featuring Abbott Laboratories, Danaher and bioMerieux Among Others - ResearchAndMarkets.com - Business Wire
August 15, 2022 | finance.yahoo.com
Outlook on the Clinical Chemistry Global Market to 2027 - Featuring Abbott Laboratories, Danaher and Hitachi Among Others - Yahoo Finance
August 15, 2022 | globenewswire.com
Outlook on the Clinical Chemistry Global Market to 2027 - Featuring Abbott Laboratories, Danaher and Hitachi Among Others - GlobeNewswire
August 12, 2022 | benzinga.com
Danaher Whale Trades For August 12 - Benzinga
August 12, 2022 | globenewswire.com
Point-of-Care Molecular Diagnostics Market Report 2022: Featuring Key Players bioMerieux, F. Hoffmann-La Roche, Danaher & Others - GlobeNewswire
August 11, 2022 | businesswire.com
Global Process Analyzer Market (2022 to 2026) - Featuring ABB, Danaher and Emerson Electric Among Others - ResearchAndMarkets.com - Business Wire
August 10, 2022 | americanbankingnews.com
Danaher Co. (NYSE:DHR) Receives $328.58 Average Price Target from Analysts
August 9, 2022 | finance.yahoo.com
Could The Danaher Corporation (NYSE:DHR) Ownership Structure Tell Us Something Useful?
August 6, 2022 | nytimes.com
Dolphin Strangers Met in the Bahamas. Things Went Swimmingly. - The New York Times
August 2, 2022 | americanbankingnews.com
Danaher (NYSE:DHR) Upgraded at StockNews.com
August 1, 2022 | nasdaq.com
Here's Why We Think Danaher (NYSE:DHR) Might Deserve Your Attention Today - Nasdaq
August 1, 2022 | americanbankingnews.com
Danaher (NYSE:DHR) Price Target Raised to $323.00
July 30, 2022 | msn.com
Danaher Whale Trades For July 28
July 30, 2022 | nasdaq.com
Interesting DHR Put And Call Options For September 9th
July 29, 2022 | benzinga.com
Here's How Much You Would Have Made Owning Danaher Stock In The Last 5 Years - Benzinga
July 28, 2022 | benzinga.com
Danaher Whale Trades For July 28 - Benzinga
July 27, 2022 | fool.com
1 Conglomerate Stock You'll Be Happy You Own In 2032 - The Motley Fool
July 27, 2022 | benzinga.com
Danaher And 2 Other Stocks Insiders Are Selling - Benzinga - Benzinga
July 27, 2022 | nasdaq.com
1 Conglomerate Stock You'll Be Happy You Own In 2032 - Nasdaq
July 27, 2022 | businesswire.com
Genetic Testing Global Market Report 2022: Featuring Key Players Abbott Laboratories, Danaher Corporation, Illumina, BioRad Laboratories & F Hoffmann-La Roche - ResearchAndMarkets.com - Business Wire
July 27, 2022 | americanbankingnews.com
Walter G. Lohr Sells 3,906 Shares of Danaher Co. (NYSE:DHR) Stock
July 27, 2022 | americanbankingnews.com
Q3 2022 EPS Estimates for Danaher Co. (NYSE:DHR) Cut by Analyst
July 26, 2022 | nasdaq.com
Q2 Earnings Season Scorecard and Analyst Reports for Broadcom, Oracle, & Danaher - Nasdaq
July 26, 2022 | finance.yahoo.com
Q2 Earnings Season Scorecard and Analyst Reports for Broadcom, Oracle, & Danaher
July 26, 2022 | americanbankingnews.com
Cowen Trims Danaher (NYSE:DHR) Target Price to $340.00
See More Headlines
Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Company Calendar

Ex-Dividend for 7/29 Dividend
6/23/2022
Last Earnings
7/21/2022
Dividend Payable
7/29/2022
Today
8/17/2022
Next Earnings (Estimated)
10/20/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Process control instruments
Sub-Industry
Industrial Conglomerates
Sector
Multi-Sector Conglomerates
Current Symbol
NYSE:DHR
CUSIP
23585110
CIK
313616
Web
www.danaher.com
Phone
(202) 828-0850
Fax
202-828-0860
Employees
80,000
Year Founded
1984

Price Target and Rating

Average Stock Price Forecast
$326.50
High Stock Price Forecast
$370.00
Low Stock Price Forecast
$265.00
Forecasted Upside/Downside
+10.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$8.49
Trailing P/E Ratio
35.01
Forward P/E Ratio
28.58
P/E Growth
2.42
Net Income
$6.43 billion
Net Margins
20.61%
Pretax Margin
24.79%
Return on Equity
18.57%
Return on Assets
9.55%

Debt

Debt-to-Equity Ratio
0.45
Current Ratio
1.75
Quick Ratio
1.32

Sales & Book Value

Annual Sales
$29.45 billion
Price / Sales
7.34
Cash Flow
$13.37 per share
Price / Cash Flow
22.24
Book Value
$61.77 per share
Price / Book
4.81

Miscellaneous

Outstanding Shares
727,445,000
Free Float
645,971,000
Market Cap
$216.25 billion
Optionable
Optionable
Beta
0.86

Social Links


Key Executives

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













DHR Stock - Frequently Asked Questions

Should I buy or sell Danaher stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DHR shares.
View DHR analyst ratings or view top-rated stocks.

What is Danaher's stock price forecast for 2022?

12 Wall Street research analysts have issued 1 year price objectives for Danaher's stock. Their DHR share price forecasts range from $265.00 to $370.00. On average, they expect the company's share price to reach $328.58 in the next twelve months. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for DHR or view top-rated stocks among Wall Street analysts.

How have DHR shares performed in 2022?

Danaher's stock was trading at $329.01 at the beginning of 2022. Since then, DHR shares have decreased by 8.7% and is now trading at $300.48.
View the best growth stocks for 2022 here.

Are investors shorting Danaher?

Danaher saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 3,890,000 shares, a decrease of 15.6% from the July 15th total of 4,610,000 shares. Based on an average daily trading volume, of 2,370,000 shares, the short-interest ratio is currently 1.6 days. Currently, 0.6% of the shares of the stock are short sold.
View Danaher's Short Interest.

When is Danaher's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our DHR earnings forecast.

How were Danaher's earnings last quarter?

Danaher Co. (NYSE:DHR) posted its quarterly earnings results on Thursday, July, 21st. The conglomerate reported $2.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.35 by $0.41. The conglomerate earned $7.75 billion during the quarter, compared to analyst estimates of $7.29 billion. Danaher had a net margin of 20.61% and a trailing twelve-month return on equity of 18.57%. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the company earned $2.46 EPS.
Read the conference call transcript.

How often does Danaher pay dividends? What is the dividend yield for Danaher?

Danaher announced a quarterly dividend on Tuesday, May 10th. Investors of record on Friday, June 24th will be given a dividend of $0.25 per share on Friday, July 29th. This represents a $1.00 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date is Thursday, June 23rd.
Read our dividend analysis for DHR.

Is Danaher a good dividend stock?

Danaher (NYSE:DHR) pays an annual dividend of $1.00 per share and currently has a dividend yield of 0.33%. The company has been increasing its dividend for 6 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 11.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 9.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What is Rainer M. Blair's approval rating as Danaher's CEO?

27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Danaher own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).

What is Danaher's stock symbol?

Danaher trades on the New York Stock Exchange (NYSE) under the ticker symbol "DHR."

Who are Danaher's major shareholders?

Danaher's stock is owned by a number of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.11%), Parnassus Investments LLC (0.64%), DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main (0.55%), Bishop Rock Capital L.P. (0.54%), Pictet Asset Management SA (0.47%) and UBS Asset Management Americas Inc. (0.46%). Insiders that own company stock include Angela S Lalor, Angela S Lalor, Brian W Ellis, Daniel L Comas, Daniel Raskas, Donald J Ehrlich, Elias A Zerhouni, Joakim Weidemanis, John T Schwieters, Linda P Hefner, Matthew Mcgrew, Mitchell P Rales, Rainer Blair, Robert S Lutz, Teri List, Thomas Patrick Joyce Jr, Walter G Lohr, William K Daniel and William King.
View institutional ownership trends.

How do I buy shares of Danaher?

Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Danaher's stock price today?

One share of DHR stock can currently be purchased for approximately $300.48.

How much money does Danaher make?

Danaher (NYSE:DHR) has a market capitalization of $218.58 billion and generates $29.45 billion in revenue each year. The conglomerate earns $6.43 billion in net income (profit) each year or $8.49 on an earnings per share basis.

How many employees does Danaher have?

The company employs 80,000 workers across the globe.

Does Danaher have any subsidiaries?
The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
When was Danaher founded?

Danaher was founded in 1984.

How can I contact Danaher?

Danaher's mailing address is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. The official website for the company is www.danaher.com. The conglomerate can be reached via phone at (202) 828-0850, via email at investor.relations@danaher.com, or via fax at 202-828-0860.

This page (NYSE:DHR) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.